← Back to The Absolute Effect
Testicular Germ-Cell Tumours · Medical Oncology · Relapsed seminoma · second-line salvage

VeIP in recurrent seminoma

In patients with recurrent seminoma after cisplatin-based chemotherapy, can VeIP produce durable remission?

Seminoma-specific retrospective series

Population
24

Study population as reported in the cited publication; cohort sizes and denominators are stated where available.

Evidence type
Seminoma-specific

Not all evidence is randomized, comparative, or seminoma-specific.

Reported outcomes

Twenty of 24 patients (83%) achieved complete remission with VeIP alone; one additional patient became disease-free after resection of residual disease. Thirteen of 24 (54%) were long-term survivors at a median follow-up of 7 years.

Complete remission with VeIP alone20/24
Long-term survivors13/24

Bars visualize source-reported percentages; where the denominator is shown, it is the observed count/denominator rather than a comparative treatment effect. NNT is not calculated for single-arm cohorts or non-randomized comparisons.

Interpretation and limitations

This is the most directly relevant seminoma-specific regimen series in this set. It is small and retrospective, not a randomized trial. Seven patients had previously received pelvic radiotherapy.

Guideline context: ESMO–EURACAN recommends standard-dose VIP/PEI, TIP or VeIP as conventional first salvage options after relapse following cisplatin-based chemotherapy. NCCN Testicular Cancer Guidelines Insights (Version 2.2025) is a contemporary US guideline source. The study summarized here is not necessarily seminoma-specific; histology scope is stated explicitly below.

Guidelines: ESMO–EURACAN 2022 · NCCN Insights v2.2025

Primary study source

Miller KD, Loehrer PJ, Gonin R, Einhorn LH. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol. 1997;15:1427–1431.

Original study / PubMed / registry ↗

Evidence review date: 18 October 2026. Confirm regimen choice and dose schedules against current guideline text and an expert germ-cell tumour multidisciplinary team.